Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer

Table 6 ORs for gastric non-cardia cancer and peptic ulcer development with IL-4-168 and -590 polymorphisms

	Genotype	1NUD (n)	Cancer (n)	OR	95% CI	P value	Ulcer (n)	OR	95% CI	P value
IL-4-168	T/T	743	744	-
	T/C	332	271	0.81	0.67-0.98	0.03
	C/C	24	27	1.12	0.64-2.00	0.70
	C carrier	356	298	0.81	0.69-1.00	0.05
IL-4-590	C/C	1716	591	-			46	-
	C/T	1039	242	0.68	0.57-0.80	< 0.01	18	0.65	0.37-1.10	0.12
	T/T	229	28	0.36	0.24-0.53	< 0.01	2	0.33	0.08-1.35	0.12
	T carrier	1268	270	0.61	0.53-0.73	< 0.01	20	0.58	0.34-0.99	0.05

¹NUD includes patients with gastritis without gastric cancer and peptic ulcer, and atrophic gastritis. Because we deleted a number of gastric cardia cancer patients, the number of cancer patients in this Table does not match that in Table 2.